Skip to main content

Advertisement

SpringerLink
Log in

Neuroendocrine carcinoma of the esophagus: clinicopathologic study of 10 cases and verification of the diagnostic utility of mASH1, NeuroD1, and PGP9.5

  • Original Article
  • Published:
Esophagus Aims and scope Submit manuscript

Abstract

Background

Neuroendocrine carcinoma (NEC) of the esophagus is a rare histologic type that is aggressive and grows rapidly. Immunohistochemistry with conventional antibodies, such as synaptophysin, chromogranin A, and CD56, is widely performed. Several novel neuroendocrine markers, such as mammalian achaete-scute homolog 1 (mASH1), NeuroD1, and PGP9.5, were recently proposed.

Methods

From 1115 consecutive cases with esophageal cancer, 10 NEC cases (0.9 %) were enrolled and the clinicopathologic parameters, including prognosis, were compared with those of 32 squamous cell carcinomas (SCC) and 30 basaloid squamous carcinomas (BSC). Immunohistochemistry for mASH1, NeuroD1, PGP9.5 and for conventional antibodies was performed. Both monoclonal and polyclonal antibodies for NeuroD1 and PGP9.5 were evaluated.

Results

Six NEC cases were diagnosed as T1b (submucosal invasion), four of which were endoscopically resected. The remaining four cases with T3 or T4 died of the disease within 37 months. Of the six patients with T1b, three are alive with no evidence of disease for more than 50 months, although the prognosis is worse for NEC than for SCC and BSC. The mASH1, NeuroD1-monoclonal, NeuroD1-polyclonal, PGP9.5-monoclonal, and PGP9.5-polyclonal immunohistochemical markers were positive in 8, 8, 1, 7, and 6 NEC cases, respectively. The number of mASH1-positive cases and synaptophysin-positive cases was the same. mASH1 had good concordance with chromogranin A and CD56, and was superior to other novel antibodies. mASH1 had excellent specificity and sensitivity for NEC.

Conclusion

Esophageal NEC has a worse prognosis than SCC and BSC, even in T1b patients. mASH1 is an excellent novel marker for diagnosing esophageal NEC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Japan Esophageal Society. Comprehensive registry of esophageal cancer in Japan (1995, 1996, 1997). 2nd ed. 2001. http://esophagus.jp/crec.html. Accessed 7 Jan 2014.

  2. Japan Esophageal Society. Comprehensive registry of esophageal cancer in Japan (1998, 1999) and long-term results of esophagectomy in Japan (1988–1997). 3rd ed. 2002. http://esophagus.jp/crec.html. Accessed 7 Jan 2014.

  3. Ide H. Macroscopic findings of non-squamous cell carcinoma of the esophagus. Stomach Intest. 2005;40:279–87 (in Japanese with English Abstract).

    Google Scholar 

  4. Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Geneva: WHO Press; 2010.

    Google Scholar 

  5. Yamamoto J, Ohshima K, Ikeda S, Iwashita A, Kikuchi M. Primary esophageal small cell carcinoma with concomitant invasive squamous cell carcinoma or carcinoma in situ. Hum Pathol. 2003;34:1108–15.

    Article  CAS  PubMed  Google Scholar 

  6. Yun JP, Zhang MF, Hou JH, Tian QH, Fu J, Liang XM, et al. Primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical features of 21 cases. BMC Cancer. 2007;7:38.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Kuo CH, Hsieh CC, Chan ML, Li AF, Huang MH, Hsu WH, et al. Small cell carcinoma of the esophagus: a report of 16 cases from a single institution and literature review. Ann Thorac Surg. 2011;2:373–8.

    Article  Google Scholar 

  8. Lu J, Xue LY, Lu N, Zou SM, Liu XY, Wen P. Superficial primary small cell carcinoma of the esophagus: clinicopathological and immunohistochemical analysis of 15 cases. Dis Esophagus. 2010;23:153–9.

    Article  CAS  PubMed  Google Scholar 

  9. Noguchi T, Takeno S, Kato T, Wada S, Noguchi T, Uchida Y, et al. Small cell carcinoma of the esophagus; clinicopathological and immunohistochemical analysis of six cases. Dis Esophagus. 2003;16:252–8.

    Article  CAS  PubMed  Google Scholar 

  10. Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus. 2009;6:71–94.

    Article  Google Scholar 

  11. Hudson E, Powell J, Mukherjee S, Crosby TD, Brewster AE, Maughan TS, et al. Small cell oesophageal carcinoma: an institutional experience and review of the literature. Br J Cancer. 2007;96:708–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Ku GY, Minsky BD, Rusch VW, Bains M, Kelsen DP, Ilson DH. Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience. Ann Oncol. 2008;19:533–7.

    Article  CAS  PubMed  Google Scholar 

  13. Chin K, Baba S, Hosaka H, Ishiyama A, Mizunuma N, Shinozaki E, et al. Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience. Jpn J Clin Oncol. 2008;38:426–31.

    Article  PubMed  Google Scholar 

  14. Serrano MF, El-Mofty SK, Gnepp DR, Lewis JS Jr. Utility of high molecular weight cytokeratins, but not p63, in the differential diagnosis of neuroendocrine and basaloid carcinomas of the head and neck. Hum Pathol. 2008;39:591–8.

    Article  CAS  PubMed  Google Scholar 

  15. Maru DM, Khurana H, Rashid A, Correa AM, Anandasabapathy S, Krishnan S, et al. Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus. Am J Surg Pathol. 2008;32:1404–11.

    Article  PubMed  Google Scholar 

  16. Li AF, Li AC, Hsu CY, Li WY, Hsu HS, Chen JY. Small cell carcinomas in gastrointestinal tract: immunohistochemical and clinicopathological features. J Clin Pathol. 2010;63:620–5.

    Article  PubMed  Google Scholar 

  17. Shida T, Furuya M, Nikaido T, Kishimoto T, Koda K, Oda K, et al. Aberrant expression of human achaete-scute homologue gene 1 in the gastrointestinal neuroendocrine carcinomas. Clin Cancer Res. 2005;11:450–8.

    CAS  PubMed  Google Scholar 

  18. Rapa I, Ceppi P, Bollito E, Rosas R, Cappia S, Bacillo E, et al. Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Mod Pathol. 2008;21:700–7.

    Article  CAS  PubMed  Google Scholar 

  19. Shida T, Furuya M, Kishimoto T, Nikaido T, Tanizawa T, Koda K, et al. The expression of NeuroD and mASH1 in the gastroenteropancreatic neuroendocrine tumors. Mod Pathol. 2008;21:1363–70.

    Article  CAS  PubMed  Google Scholar 

  20. Fujii A, Kamiakito T, Takayashiki N, Fujii T, Tanaka A. Neuroendocrine tissue-specific transcription factor, BETA2/NeuroD, in gastric carcinomas: a comparison with chromogranin A and synaptophysin expressions. Pathol Res Pract. 2003;199:513–9.

    Article  CAS  PubMed  Google Scholar 

  21. Sasaki H, Yukiue H, Moriyama S, Kobayashi Y, Nakashima Y, Kaji M, et al. Expression of the protein gene product 9.5, PGP9.5, is correlated with T-status in non-small cell lung cancer. Jpn J Clin Oncol. 2001;31:532–5.

    Article  CAS  PubMed  Google Scholar 

  22. Takase T, Hibi K, Yamazaki T, Nakayama H, Taguchi M, Kasai Y, et al. PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology. 2003;50:1278–80.

    CAS  PubMed  Google Scholar 

  23. Arai T, Aida J, Nakamura K, Ushio Y, Takubo K. Clinicopathologic characteristics of basaloid squamous carcinoma of the esophagus. Esophagus. 2011;8:169–77.

    Article  Google Scholar 

  24. Lv J, Liang J, Wang J, Wang L, He J, Xiao Z, et al. Primary small cell carcinoma of the esophagus. J Thorac Oncol. 2008;3:1460–5.

    Article  PubMed  Google Scholar 

  25. Takubo K, Nakamura K, Sawabe M, Arai T, Esaki Y, Miyashita M, et al. Primary undifferentiated small cell carcinoma of the esophagus. Hum Pathol. 1999;30:216–21.

    Article  CAS  PubMed  Google Scholar 

  26. Koide N, Saito H, Suzuki A, Sato T, Koiwai K, Nakamura N, et al. Clinicopathologic features and histochemical analyses of proliferative activity and angiogenesis in small cell carcinoma of the esophagus. J Gastroenterol. 2007;42:932–8.

    Article  PubMed  Google Scholar 

  27. Chen SB, Yang JS, Yang WP, Weng HR, Li H, Liu DT, et al. Treatment and prognosis of limited disease primary small cell carcinoma of esophagus. Dis Esophagus. 2011;24:114–9.

    Article  PubMed  Google Scholar 

  28. Huang Q, Wu H, Nie L, Shi J, Lebenthal A, Chen J, et al. Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. Am J Surg Pathol. 2013;37:467–83.

    Article  PubMed  Google Scholar 

  29. Vos B, Rozema T, Miller RC, Hendlisz A, Van Laethem JL, Khanfir K, et al. Small cell carcinoma of the esophagus: a multicentre Rare Cancer Network study. Dis Esophagus. 2011;24:258–64.

    Article  PubMed  Google Scholar 

  30. Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol. 2008;32:719–31.

    Article  PubMed  Google Scholar 

  31. Marchevsky AM, Gal AA, Shah S, Koss MN. Morphometry confirms the presence of considerable nuclear size overlap between “small cells” and “large cells” in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol. 2001;116:466–72.

    Article  CAS  PubMed  Google Scholar 

  32. Hiroshima K, Iyoda A, Shida T, Shibuya K, Iizasa T, Kishi H, et al. Distinction of pulmonary large cell neuroendocrine carcinoma from small cell lung carcinoma: a morphological, immunohistochemical, and molecular analysis. Mod Pathol. 2006;19:1358–68.

    Article  CAS  PubMed  Google Scholar 

  33. Helpap B, Köllermann J. Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence? Virchows Arch. 2001;438:86–91.

    Article  CAS  PubMed  Google Scholar 

  34. Howe MC, Chapman A, Kerr K, Dougal M, Anderson H, Hasleton PS. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology. 2005;46:195–201.

    Article  CAS  PubMed  Google Scholar 

  35. Jiang SX, Kameya T, Asamura H, Umezawa A, Sato Y, Shinada J, et al. hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors. Mod Pathol. 2004;17:222–9.

    Article  CAS  PubMed  Google Scholar 

  36. Oyama K, Sanno N, Teramoto A, Osamura RY. Expression of neuro D1 in human normal pituitaries and pituitary adenomas. Mod Pathol. 2001;14:892–9.

    Article  CAS  PubMed  Google Scholar 

  37. Larsen CN, Krantz BA, Wilkinson KD. Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry. 1998;37:3358–68.

    Article  CAS  PubMed  Google Scholar 

  38. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol. 1999;155:711–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. Campbell LK, Thomas JR, Lamps LW, Smoller BR, Folpe AL. Protein gene product 9.5 (PGP 9.5) is not a specific marker of neural and nerve sheath tumors: an immunohistochemical study of 95 mesenchymal neoplasms. Mod Pathol. 2003;16:963–9.

    Article  PubMed  Google Scholar 

  40. Wilson PO, Barber PC, Hamid QA, Power BF, Dhillon AP, Rode J, et al. The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol. 1988;69:91–104.

    CAS  PubMed Central  PubMed  Google Scholar 

  41. Tezel E, Hibi K, Nagasaka T, Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res. 2000;6:4764–7.

    CAS  PubMed  Google Scholar 

  42. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res. 2002;8:192–5.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors gratefully acknowledge Dr. Toichiro Takizawa, former professor of Tokyo Medical and Dental University, for providing both the opportunity for this study and his sincere encouragement.

Ethical Statement

About the submission of our manuscript titled “Neuroendocrine carcinoma of the esophagus: Clinicopathologic study of 10 cases and verification of the diagnostic utility of mASH1, NeuroD1, and PGP9.5”, all of authors here declare that this study was performed in accordance with the World Medical Association and the Declaration of Helsinki. The ethics committee of Tokyo Medical and Dental University approved the protocols (Registration No. 1026).

Conflict of interest

There are no financial or other relations that could lead to a conflict of interest.

Author information

Authors and Affiliations

  1. Department of Human Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo, 113-8519, Japan

    Naoki Akazawa, Hiroshi Kawachi, Keisuke Kitagaki, Masaki Sekine, Maki Kobayashi & Yoshinobu Eishi

  2. Latin American Collaborative Research Center, Tokyo Medical and Dental University, Santiago, Chile

    Hiroshi Kawachi & Maki Kobayashi

  3. Section of Molecular Pathophysiology, Graduate School of Health Care Sciences, Tokyo Medical and Dental University, Tokyo, Japan

    Takayuki Seki, Satoko Kawaragi & Miki Yuzawa

  4. Department of Esophageal and General Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

    Yasuaki Nakajima & Tatsuyuki Kawano

Authors
  1. Naoki Akazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Kawachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Keisuke Kitagaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takayuki Seki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Satoko Kawaragi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Miki Yuzawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masaki Sekine
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Maki Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasuaki Nakajima
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tatsuyuki Kawano
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshinobu Eishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Kawachi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akazawa, N., Kawachi, H., Kitagaki, K. et al. Neuroendocrine carcinoma of the esophagus: clinicopathologic study of 10 cases and verification of the diagnostic utility of mASH1, NeuroD1, and PGP9.5. Esophagus 11, 245–257 (2014). https://doi.org/10.1007/s10388-014-0444-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10388-014-0444-6

Keywords

Search

Navigation